Subtype-Selective GABAA Receptor Modulation Yields a Novel Pharmacological Profile: The Design and Development of TPA023
The DOI matches its Crossref record; 110 of the 111 references it cites were found in a registry or an index.
Abstract
TPA023 is a GABA(A) alpha2/alpha3 subtype-selective modulator which in preclinical species has anxiolytic-like activity but does not produce sedative-like properties and is without abuse potential. It has good oral bioavailability in rat and dog but not in rhesus monkey (respective oral bioavailability values of 36, 54, and 1%), and in all the three species the half-life after i.v. administration was relatively short (0.6-1.5 h). The plasma concentrations of TPA023 required to produce 50% receptor occupancy were 21-25, 19, and 9 ng/mL in rats, baboons, and humans, respectively. In man, TPA023 has a half-life of around 3-6h when administered as an immediate release formulation, but exposure was more prolonged when it was formulated into a controlled release, gel extrusion module (GEM) tablet. In vivo metabolism was via t-butyl hydroxylation and N-deethylation. A drug-drug interaction study with itraconazole confirmed in vitro metabolic results implicating CYP3A enzymes as the major contributors to in vivo oxidative metabolism. The maximum tolerated doses in healthy, normal volunteers were 2 and 8mg for the immediate-release and GEM formulations, respectively. A post hoc analysis of three separate Phase IIa studies, all of which were halted prematurely, showed that TPA023 reduced scores on the Hamilton Anxiety Scale to a significantly greater extent than placebo. In addition, TPA023 has recently been reported to produce a trend toward improved cognitive performance in a small group of schizophrenia patients. Collectively, these data demonstrate that the alpha2/alpha3-selective partial agonist efficacy of TPA023 translates into a novel pharmacological profile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GABA-gated currents increase hyperbolically with increasing diazepam concentrations in cellular models (Berezhnoy et al., 2008; Wongsamitkul et al., 2017), including recombinant human GABA-A receptors (Atack, 2009) (Figure 3a).”
From Pharmacological principles for safe benzodiazepine and Z-drug dose reduction (2026) · cites this paper as Atack, 2009
In the citing paper
“even though the anxiolytic profile of these compounds remains to be determined [164]”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [164]
In the citing paper
“In healthy humans, only TPA023 with α1 antagonistic properties, but not MRK-409 with weak α1 partial agonistic effects, causes sedation-free anxiolysis (de Haas et al., 2007), as well as in patients with GAD as shown in Phase 2 trials (Atack, 2009).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Atack, 2009
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Wisden, W., Laurie, D., Monyer, H., & Seeburg, P. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-03-01040.1992 · Cited by 1,543
GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain
Pirker, S., Schwarzer, C., Wieselthaler, A., Sieghart, W., & Sperk, G. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00442-5 · Cited by 1,344
Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.
Sieghart, W. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06840-1 · Cited by 1,301
Fritschy, J., & Mohler, H. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903590111 · Cited by 1,244
Selective antagonists of benzodiazepines
Hunkeler, W., Möhler, H., Pieri, L., Polc, P., Bonetti, E. P., Cumin, R., Schaffner, R., & Haefely, W. (1981) · Nature · doi:10.1038/290514a0 · Cited by 1,232
Barnard, E. A., Skolnick, P., Olsen, R. W., Möhler, H., Sieghart, W., Biggio, G., Bræstrup, C., Bateson, A. N., & Langer, S. Z. (1998) · PubMed · Cited by 1,204
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Olsen, R. W., & Sieghart, W. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.00505 · Cited by 1,064
Research works printed but not linked: 6
- 2007, NME digest, Drug News & Perspectives, 20, 635
- 2008, Psychopharmacologic drugs, Drug Data Report, 30, 482
- Atack, 2009, GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics, Current Topics in Medicinal Chemistry
- Atack, 2009, MRK-409, a GABAA receptor subtype-selective agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in man, Journal of Psychopharmacology
- Fischer, 2009, Evaluation of the role of GABAA receptors containing α3 subunits in the therapeutic and unwanted side effects of benzodiazepine-type drugs in monkeys
- Volz, 2007, Benzodiazepines for schizophrenia (Review), Cochrane Database of Systematic Reviews, 1, CD006391
Cited by
The GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
“…at a2, a3 and a5 but not at a1 GABAA receptors, such as L-838 417 (McKernan et al., 2000) or TPA023, a partial agonist at a2 and a3 receptors (Atack, 2009), provided anxiolytic activity devoid of sedation and with no or low dependence liability compared to classical benzodiazepines (Ator,…”
BackgroundRudolph, U., & Möhler, H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135947 · Cited by 319
“5 mg), in contrast to lorazepam (2 mg), was inactive in tests of sedation (visual alertness), cognition (word and picture recognition), and posture (body sway) (95).”
BackgroundInfluentialSartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Vinkers, C. H., & Olivier, B. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/416864 · Cited by 195
Mosienko, V., Beis, D. M., Pasqualetti, M., Waider, J., Matthes, S., Qadri, F., Bäder, M., & Alenina, N. V. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.06.005 · Cited by 129
Metadata
- Authors
- Atack, J. R.
- Affiliations
- Janssen Research & Development (United States) (US)
- Corresponding author
- Atack, John R.
- ORCID
- Atack, John R.
- Venue
- Advances in Pharmacology
- Publisher
- Elsevier
- Published
- 2009
- Volume
- 57
- Pages
- 137-185
- ISSN
- 1054-3589 (ISSN-L)
- OpenAlex
- W1520508152
- Cited by
- 52
- References
- 111
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 4 · 2016: 2 · 2014: 5 · 2013: 3 · 2012: 6
- FWCI
- 5.57
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Advances in pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- GABAA receptor, anxiolytic effects, abuse liability, oral bioavailability, pharmacokinetics, drug-drug interactions, CYP3A metabolism, itraconazole, controlled-release formulation, maximum tolerated dose, schizophrenia, cognitive performance, Hamilton Anxiety Rating Scale
- MeSH terms
- Amino Acid Sequence, Animals, Anxiety, Drug Evaluation, Preclinical, Humans, Molecular Sequence Data, Pyridazines, Receptors, GABA-A, Triazoles, Drug Design, Protein Subunits
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subtype-Selective GABAA Receptor Modulation Yields a Novel Pharmacological Profile: The Design and Development of TPA023. https://app.cochat.ai/papers/10.1016/s1054-3589(08)57004-9
- The paper
- Atack, J. R. (2009). Subtype-Selective GABAA Receptor Modulation Yields a Novel Pharmacological Profile: The Design and Development of TPA023. Advances in Pharmacology. https://doi.org/10.1016/s1054-3589(08)57004-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.